Health-related quality of life in transplant-eligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, bortezomib, and dexamethasone: Patient-reported outcomes from GRIFFIN Journal Article
| Authors: | Silbermann, R.; Laubach, J.; Kaufman, J. L.; Sborov, D. W.; Reeves, B.; Rodriguez, C.; Chari, A.; Costa, L. J.; Anderson, L. D. Jr; Nathwani, N.; Shah, N.; Bumma, N.; Holstein, S. A.; Costello, C.; Jakubowiak, A.; Orlowski, R. Z.; Shain, K. H.; Cowan, A. J.; Gries, K. S.; Pei, H.; Cortoos, A.; Patel, S.; Lin, T. S.; Voorhees, P. M.; Usmani, S. Z.; Richardson, P. G. |
| Article Title: | Health-related quality of life in transplant-eligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, bortezomib, and dexamethasone: Patient-reported outcomes from GRIFFIN |
| Abstract: | In the phase 2 GRIFFIN trial (ClinicalTrials.gov identifier: NCT02874742), daratumumab added to lenalidomide, bortezomib, and dexamethasone (D-RVd) improved depth of response and progression-free survival (PFS) versus lenalidomide, bortezomib, and dexamethasone (RVd) alone in transplant-eligible (TE) patients with newly diagnosed multiple myeloma (NDMM). Here, we present patient-reported outcomes (PROs) collected using the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 30-item (QLQ-C30), EORTC Quality of Life Questionnaire Multiple Myeloma Module 20-item (QLQ-MY20), and EuroQol 5-Dimension 5-Level (EQ-5D-5L) tools on day 1 of cycles 1, 2, and 3; on day 21 of cycle 4 (end of induction therapy); on day 1 of cycle 5; on day 21 of cycle 6 (end of posttransplant consolidation therapy); and at months 6, 12, 18, and 24 of maintenance therapy. Meaningful improvements from baseline were seen in most of the PRO scales with both treatments after consolidation and were sustained for at least 2 years of maintenance treatment. Large reductions from baseline (~20 points) were especially observed in pain symptoms for both treatment groups, although these were numerically higher for patients receiving D-RVd during the majority of the time points. In addition, improvements in key scales, such as global health status, fatigue symptoms, and physical functioning, were also seen with both D-RVd and RVd. These improvements in health-related quality of life contribute to the totality of evidence supporting the improvement in clinical outcomes such as response rates and PFS with D-RVd in induction, consolidation, and maintenance therapy in TE patients with NDMM. © 2024 The Authors. American Journal of Hematology published by Wiley Periodicals LLC. |
| Keywords: | adult; controlled study; aged; middle aged; major clinical study; lenalidomide; clinical trial; constipation; fatigue; outcome assessment; follow up; antineoplastic agent; cancer immunotherapy; progression free survival; quality of life; bortezomib; multiple myeloma; phase 2 clinical trial; randomized controlled trial; antineoplastic combined chemotherapy protocols; maintenance therapy; dexamethasone; monoclonal antibody; dyspnea; questionnaire; insomnia; social support; antibodies, monoclonal; multicenter study; transplantation conditioning; anxiety disorder; nausea and vomiting; anxiety; patient reported outcome measures; drug therapy; short form 36; sleep disorder; pain assessment; visual analog scale; adverse drug reaction; creatinine clearance; chronic fatigue syndrome; patient-reported outcome; social interaction; differentiation therapy; body weight loss; beck anxiety inventory; quality of life assessment; humans; human; male; female; article; cognitive function test; daratumumab; depression assessment; european organization for research and treatment of cancer quality of life questionnaire core 30; european quality of life 5 dimensions questionnaire; transplant eligible patient |
| Journal Title: | American Journal of Hematology |
| Volume: | 99 |
| Issue: | 7 |
| ISSN: | 0361-8609 |
| Publisher: | John Wiley & Sons, Inc. |
| Date Published: | 2024-07-01 |
| Start Page: | 1257 |
| End Page: | 1268 |
| Language: | English |
| DOI: | 10.1002/ajh.27326 |
| PUBMED: | 38622840 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Article -- Source: Scopus |
